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Abstract
Purpose Natural antioxidants are considered as promising compounds in the prevention/treatment of osteoporosis. We stud-
ied the ability of purified δ-tocotrienol (δ-TT) isolated from a commercial palm oil (Elaeis guineensis) fraction to protect 
osteoblast MC3T3-E1 and osteocyte MLO-Y4 cells against tert-butyl hydroperoxide (t-BHP)-induced oxidative damage and 
the mechanisms involved in its protective action in MC3T3-E1.
Methods MC3T3-E1 and MLO-Y4 cells were treated with δ-TT (1.25–20 µg/ml for 2 h) followed by t-BHP at 250 µM or 
125 µM for 3 h, respectively. MTT test was used to measure cell viability. Apoptotic cells were stained with Hoechst-33258 
dye. Intracellular ROS levels were measured by dichlorofluorescein CM-DCFA. The OPT fluorimetric assay was used to 
detect the reduced glutathione to oxidized glutathione ratio (GSH/GSSG) contents.
Results δ-TT significantly prevented the effects of t-BHP on cell viability and apoptosis reaching a maximum protective 
activity at 10 and 5 µg/ml in MC3T3-E1 and MLO-Y4 cells, respectively. This protective effect was due to a reduction of 
intracellular ROS levels and an increase in the defense systems shown by the increase in the GSH/GSSG. GSH loss induced 
by an inhibitor of GSH synthesis significantly reduced the δ-TT-positive effect on ROS levels. δ-TT prevention of oxidative 
damage was completely removed by combined treatment with the specific inhibitors of PI3K/AKT (LY294002) and Nrf2 
(ML385).
Conclusions The δ-TT protective effect against oxidative damage in MC3T3-E1 cells is due to a reduction of intracellular 
ROS levels and an increase of the GSH/GSSG ratio, and involves an interaction between the PI3K/Akt–Nrf2 signaling 
pathways.




ROS  Reactive oxygen species
t-BHP  Tert-butyl hydroperoxide
FPP  Farnesylpyrophosphate
GGPP  Geranylgeranylpyrophosphate
CM-DCFA  5(6)-Carboxy-2′:7-dichlorofluorescein 
diacetate
GSH  Glutathione
GSSG  Glutathione disulfide




Several studies have shown that oxidative stress due to 
increased production of reactive oxygen species (ROS) or 
reduction of antioxidant defense systems exerts a crucial role 
in the development of age-related diseases including bone 
diseases such as osteoporosis [1]. Bone structural integ-
rity is preserved by removal of old bone by osteoclasts and 
deposition of new bone in place by osteoblasts. Assembly 
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of osteoclasts and osteoblasts into temporary anatomical 
structures called basic multicellular units accomplishes 
this process called remodeling. Any factor that destroys the 
coupling between osteoblast and osteoclast action leads to 
a reduction in bone mass density and quality resulting in a 
reduction in bone strength and increased risk of fracture as 
occurs in osteoporosis. Oxidative damage in bone has been 
related to an increase in the number [2, 3] and activity of 
osteoclasts mediated by an increased expression of receptor 
activator of NF-kappaB ligand (RANKL) in osteoblasts [4].
It is also well known that ROS can significantly affect the 
generation and the survival of osteoblasts and osteocytes, 
former osteoblasts encased in the mineralized matrix which 
plays a key role in sensing and bone adaptation to mechani-
cal loading [5]. High ROS levels reduce osteoblast activity 
and differentiation [6] and, therefore, osteogenesis and bone 
mineralization [7]. In line with in vitro studies, data from 
experimental studies showing that antioxidants administra-
tion reduces bone loss induced by gonadectomy in mice [5], 
and in experimental models of Sod1 (the antioxidant gene) 
knock-out mice, show a reduction of bone mass which gets 
worse with aging [8].
Furthermore, clinical reports showed higher oxidative 
stress parameters in patients with fractures than in healthy 
subjects [9] and a marked reduction in antioxidant defenses 
in osteoporotic females [10].
Although the notion that free radicals could act as signals 
is well established, only recently it has been underlined a 
difference between oxidative stress and oxidative damage. 
Oxidative stress is a reversible alteration of redox status of 
cell compartments that precede oxidative damage. When 
the redox status of the cell becomes more reduced, oxida-
tion can be reversed by the activation of specific antioxi-
dant enzymes, whereas oxidative damage is irreversible and 
occurs when reducing systems cannot cope with the rate 
of the oxidation of cell components. Thus, the preventive 
use of antioxidant compounds that could reverse oxida-
tive stress and prevent oxidative damage could be useful to 
delay the onset of disability and promote health in an elderly 
population.
In the last decade, a strong association between a lower 
incidence of age-associated degenerative diseases and a diet 
particularly rich in fruit and vegetables which represent a 
good source of antioxidant compounds has been shown [1].
Among several natural antioxidant compounds with a 
potential therapeutic utility for the prevention and/or treat-
ment of osteoporosis, there is an increasing interest in the 
effects of vitamin E supplement. Vitamin E can be classi-
fied into tocopherols and tocotrienols (TTs). There are four 
distinct isomers (α, β, γ and δ) in each group depending on 
the position of methyl group on the chromanol ring.
For many years, α tocopherol was the main focus of 
vitamin E research, while only in the last decade the 
biological actions of TTs have been investigated. Although 
tocopherols and TTs are structurally very similar, TTs have 
been found to exhibit superior anti-inflammatory and anti-
oxidant activities [11], suggesting that TTs are the vitamin 
E that should be investigated in the twenty-first century. 
Tocopherols, in fact, revealed less efficacy than TTs in 
protecting animals from bone loss [12, 13]. Furthermore, 
the effects of tocopherol supplementation on bone mass 
are inconsistent and somehow contradictory [14, 15].
Conversely, the bone protective action of TTs mixture 
[16], purified γ-TT [17] or δ-TT [18], against ovariec-
tomy-induced osteopenia or in male osteoporosis models 
induced by testosterone-deficiency [19] or by buserelin, a 
GnRH agonist [20], has been well documented.
Furthermore, osteoporosis has been correlated with low 
intake and serum levels of vitamin E and, specifically, of 
TTs [21].
The protective action of TTs on bone seems to be 
due to positive regulation of bone turnover since TTs 
stimulate bone formation and inhibit osteoclastogenesis 
by inhibiting the mevalonate pathway [22]. Among the 
various TT isoforms, δ-TT and γ-TT are considered the 
most active isomers for bone health due to their antioxi-
dant and mevalonate suppressive activity [23]. Clinical 
studies have reported that dietary supplementation of TTs 
extracted from annatto seeds (consisting of 90% δ-TT and 
10% γ-TT) exerts a beneficial action on bone turnover in 
postmenopausal women. Interestingly, the positive action 
of TTs on bone is at least in part due to a suppression of 
oxidative stress [24].
However, the exact role of individual TT isomers in the 
regulation of bone cell activity and in the prevention or 
reduction of oxidative stress at cellular level remains to be 
clarified.
The aim of the present study was to examine the ability 
of purified δ-tocotrienol (δ-TT), extracted from a commer-
cial palm oil (Elaeis guineensis) fraction, to counteract the 
negative effects of oxidative stress on MC3T3-E1 osteoblast-
like cell or MLO-Y4 osteocyte-like cells viability. Oxidative 
stress was induced by treating cells with tert-butyl hydrop-
eroxide (t-BHP), an organic hydroperoxide widely used 
to induce oxidative stress in different cells [25] including 
MC3T3-E1 osteoblastic-like cells [26].
The present evidence showing that δ-TT protects MC3T3-
E1 cells against t-BHP-induced oxidative damage led us to 
clarify the molecular pathways involved in δ-TT activity in 
MC3T3-E1 cells.
Finally, we examined the effects of δ-TT on MLO-Y4 
cells viability and apoptosis both in basal conditions and 
against oxidative stress. Osteocytes represent a communicat-
ing cellular network within bone able to regulate bone cells 
activity in relation to strain and microdamage, thus prevent-
ing alterations in bone remodeling and bone mass [27].




Tert-butylhydroperoxide (t-BHP), LY294002, EX-527, 
ML385, farnesylpyrophosphate (FPP), geranylgeranylpy-
rophosphate (GGPP), l-buthionine-sulfoximine (BSO) were 
purchased from Sigma-Aldrich Chemical, Italy.
δ‑TT and γ‑TT purification
δ-TT and γ-TT were kindly provided by Prof. Giangiacomo 
Beretta (Department of Environmental Science and Policy, 
University of Milan). δ-TT and γ-TT were extracted by liq-
uid chromatography using LC-940 Liquid Cromatography 
instrument (Varian, Leinì, Italy) from the fraction rich in 
tocotrienols/tocopherols contained in the commercial oil 
of Elaeis guineensis (Gold Tri E 70% w/w, Golden Hope 
Bioganic, Selangor, Malaysia), as previously described [28] 
with minor modification. In particular, the automated frac-
tion collector was activated in accordance with the gamma-
TT isomer retention time window, with run-to-run adjust-
ments to compensate eventual RT and peak shape variations. 
A purity for δ-TT and γ-TT of at least > 95% was achieved. 
δ-TT and γ-TT were divided into aliquots (50 mg/ml) and 
stored at − 20 °C.
Cell culture
Murine osteoblastic cell line from ATCC (cat. Num. CRL-
2593), MC3T3-E1, was seeded in High Glucose DMEM 
(Euroclone, Italy), in the presence of 10% FBS (Sigma-
Aldrich Chemical, Italy), 2% l-glutamine, 100 µg/ml strep-
tomycin and 100 U/ml penicillin at 37 °C in 5%  CO2 atmos-
phere. Cell culture medium was replaced twice a week and 
MC3T3-E1 was trypsinized weekly.
Murine osteocyte-like cells, MLO-Y4, were a gift from 
Dr. Milena Romanello (Hospital “Santa Maria della Mis-
ericordia”, Udine, Italy). Plates of 10 mm were coated with 
type I collagen. MLOY-4 cells were cultured in α-MEM 
at 37 °C in 5%  CO2 atmosphere. The medium was supple-
mented with 5% newborn calf serum, 5% FBS and 1% peni-
cillin–streptomycin. The cells were seeded in 10 mm dishes 
and were trypsinized twice a week.
Cell viability assay
To test cells viability, MC3T3-E1 and MLO-Y4 were cul-
tured in multiwell plates. Cells were seeded at the density 
of 15 × 103 cells/well for MC3T3-E1 in 48 multiwells or 
at the density of  104 cells/well in a 24-multiwell plate for 
MLO-Y4. Briefly, after treatment, cells were incubated at 
37 °C with 0.5 mg/ml 3-(4,5-dimethyl-2-thiazolyl)-2,5-di-
phenyltetrazoliumbromide (MTT, Sigma-Aldrich Chemi-
cal, Italy) for 3 h. After the supernatant removal, formazan 
crystals were suspended in dimethyl sulfoxide. The 550 nm 
absorbance was read at a microplate spectrophotometer 
(Victor™, PerkinElmer, Italy).
Hoechst staining of apoptotic cells
Apoptotic cells were evaluated by Hoechst-33258 (Sigma-
Aldrich Chemical, Italy) staining, analyzing the chromatin 
condensation. MC3T3-E1 and MLO-Y4 cells (5 × 103 cells/
well) were seeded on 22-mm glass coverslips. Briefly, after 
treatment, the cells were fixed in 4% formaldehyde in 0.2 M 
sucrose, permeabilized with 0.1% TritonX100 in PBS for 
5 min, and marked with 10 μg/ml Hoechst-33258 for 5 min. 
The fixed cells were observed at a fluorescence microscope 
(Axioplan) using 10 × and 20 × objectives. At least, 200 cells 
were counted for each sample.
Intracellular ROS production
ROS production was evaluated using 5(6)-carboxy-2′,7-
dichlorofluorescein diacetate (CM-DCFA, Sigma-Aldrich 
Chemical, Italy 10 μM) as previously described [26]. The 
cells were treated with δ-TT (10 µg/ml) for 2 h. CM-DCFA 
was added during the last half an hour treatment. After the 
removal of CM-DCFA, t-BHP (250 µM) was added. DCF 
fluorescence was measured with a microplate spectropho-
tometer (Victor™, PerkinElmer, Italy) at the 485 nm excita-
tion and 530 nm emission wavelengths at 30, 60, 120 and 
180 min after t-BHP treatment.
Measurement of cell GSH and GSSG levels
As previously described [29], the intracellular levels of 
glutathione (GSH) and glutathione disulfide (GSSG) were 
assessed performing Hissin and Hilf [30] assay. GSH or 
GSSG serial dilutions were used to determine the standard 
curve. GSH/GSSG levels were normalized versus the total 
cellular protein amounts obtained by BCA assay.
Statistical analysis
Statistical analysis was performed by GraphPad Prism5 
(GraphPad Software San Diego, CA, USA). The results are 
expressed as the mean ± SEM of six independent experi-
ments (six replicates for each experiment) and evaluated by 
one-way ANOVA followed by post hoc Bonferroni’s test 
when data were parametric. A Kruskal–Wallis test followed 
by Dunnett’s test was used for non-parametric data. A p 
value less than 0.05 was considered significant.
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Results
Effects of δ‑TT on the viability of MC3T3‑E1 cells 
in basal conditions
We first established the effects of δ-TT on MC3T3-E1 cell 
viability in basal conditions using MTT test (Fig. 1). δ-TT 
treatment for 2 h at concentrations ranging from 2.5 to 
20 μg/ml dose-dependently increases cell viability, reaching 
a plateau starting from 10 µg/ml. These δ-TT concentrations 
have been chosen on the basis of previous in vitro studies 
[28, 31, 32].
Effects of δ‑TT on counteracting t‑BHP‑induced 
oxidative stress in MC3T3‑E1 cells
We then studied the ability of δ-TT to counteract t-BHP-
induced oxidative stress. As shown in Fig. 2a, t-BHP at the 
concentration of 250 μM for 3 h, selected on the basis of 
previous studies [26, 29], significantly reduced MC3T3-E1 
cell viability of 74.3%, compared to the control group as 
analyzed by the MTT test. Treatment of the cells with δ-TT 
at concentrations ranging from 2.5 to 20 µg/ml 2 h before 
t-BHP significantly reversed the negative action of t-BHP 
on cell viability reaching a maximal protective activity at 
10 µg/ml. This δ-TT concentration was employed in the sub-
sequent experiments. Since dietary supplementation of ann-
atto seeds (consisting of 90% δ-TT and 10% γ-TT) exerted 
bone protective effects in postmenopausal women [24], we 
examined the ability of increasing γ-TT concentrations to 
counteract t-BHP-induced cytotoxicity. We found that γ-TT 
protects MC3T3-E1 cells against oxidative damage even if 
at a lesser extent than δ-TT (Fig. 2b).
We further examined the ability of δ-TT to prevent 
t-BHP-induced apoptosis by Hoechst-332458 staining. As 
shown in Fig. 3, the pro-apoptotic action of t-BHP (250 μM 
for 3 h) was significantly reduced by δ-TT pre-treatment.
Effect of δ‑TT on ROS levels and the GSH/GSSG 
detoxifying system
δ-TT exerts its beneficial effects against t-BHP-induced oxi-
dative stress by reducing intracellular ROS levels. As shown 
in the Fig. 4, t-BHP stimulates the intracellular ROS levels 
in a statistical significant manner (267–300%) as compared 
to those detected in control-treated cells. The addition of 
δ-TT significantly reduced ROS to a level similar to the 
one detected in the control cells starting from 30 min until 
180 min of incubation. To highlight intracellular antioxi-
dant factors potentially involved in the protective effects of 
Fig. 1  Beneficial effects of δ-TT (2.5–20 µg/ml) on MC3T3-E1 cells 
viability measured by MTT assay 2 h after treatment. Data are rep-
resented as the mean ± SEM of six replicates within a single experi-
ment. *p < 0.05; **p < 0.01 vs controls
Fig. 2  Effects of a δ-TT and b γ-TT (2.5–20  µg/ml) on t-BHP-
induced cytotoxicity in MC3T3-E1 cells. Cells were pre-treated with 
δ-TT or γ-TT 2 h before being treated with t-BHP (250 µM for 3 h). 
Cell viability was measured by MTT assay. Data are the mean ± SEM 
of six replicates within a single experiment. *p < 0.05; **p < 0.01; 
***p < 0.001 vs controls. °°°p < 0.001 vs t-BHP
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δ-TT against t-BHP-induced oxidative damage, we focused 
our attention on glutathione (GSH). The GSH oxidation to 
glutathione disulfide (GSSG) and the consequent decrease 
in the GSH/GSSG ratio is related to oxidative stress and 
is considered a suitable indicator of cellular redox state 
[33]. As expected, treatment with t-BHP (30 and 180 min) 
induced a significant reduction in GSH/GSSG ratio that was 
significantly prevented by δ-TT treatment (Fig. 5a, b). The 
protective action of δ-TT on ROS levels involves a modula-
tory action on GSH synthesis. In fact, δ-TT failed to modify 
the increase in ROS levels induced by t-BHP in the presence 
of BSO (50 µM 24 h before δ-TT 10 µg/ml), an inhibitor 
of GSH synthesis [34] used at a concentration reported to 
deplete intracellular GSH levels [35, 36] (Fig. 6).
δ‑TT and antioxidant‑related signaling pathways
Various cellular signaling pathways participate to the main-
tenance of redox homeostasis. To study the mechanisms by 
which δ-TT might exert its antioxidant activity, we examined 
the possible involvement of several intracellular pathways 
such as sirtuin-1, mevalonate, Nrf2 (nuclear factor-eryth-
roid-2-related factor 2) and PI3K/Akt which are known to 
play a key role in cell survival against oxidative stress.
As shown in Fig. 7a, pre-treatment of MC3T3-E1 cells 
with the selective inhibitor of sirtuin 1, EX-527 (25 µM 2 h 
before δ-TT 10 µg/ml), fails to prevent the protective effect 
of δ-TT against oxidative stress.
Fig. 3  Effects of δ-TT on apoptosis induced by t-BHP-in MC3T3-E1 
cells. Cells were preincubated with δ-TT (10 µg/ml) 2 h before being 
treated with t-BHP (250 µM for 3 h). Apoptosis was detected by Hoe-
chst 33258 staining. a Panels show chromatin nuclear condensation 
typical of apoptotic cells. Images were taken at × 20 magnification. b 
Quantification of apoptotic cells. Data represented the mean ± SEM 
of duplicate determinations (200 cells each) of four independent 
experiments. ***p < 0.001 vs controls; °°°p < 0.001 vs t-BHP
Fig. 4  Protective effects of δ-TT on intracellular ROS levels induced 
by t-BHP in MC3T3-E1 cells by excessive generation of intracellular 
ROS stimulated. Cells were preincubated with δ-TT (10  µg/ml) 2  h 
before being treated with t-BHP (250 µM for 3 h). The intracellular 
ROS levels were measured using CM-DCFA assay. Data represented 
the mean ± SEM of 6-8 determinations ***p < 0.001 vs controls; 
°p < 0.05, °°p < 0.01 vs t-BHP
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Since δ-TT was found to down-regulate hydroxymethyl-
glutaryl-CoA reductase at the transcriptional level [37] and 
farnesylpyrophosphate (FPP) and geranylgeranylpyrophos-
phate (FPP), downstream products of mevalonate, negatively 
regulate osteoblast activity [38], we studied whether or not 
the addition of these isoprenoids could prevent the protective 
action of δ-TT against damage induced by t-BHP. Neither 
FPP nor GGPP (5 µM 2 h before δ-TT 10 µg/ml) could coun-
teract the δ-TT protective effect against oxidative damage on 
cell viability (Fig. 7b).
We next studied the PI3K/Akt signaling pathway which is 
involved in the prevention of oxidative stress-induced apop-
tosis [39]. Pre-treatment with LY294002 (10 µM, 2 h before 
δ-TT 10 µg/ml), a PI3K-specific inhibitor, exacerbated the 
cytotoxic effect of t-BHP on MC3T3-E1 cell viability but 
partially reversed the protective effect of δ-TT (Fig. 8a).
Finally, to evaluate the involvement of the Nrf2 pathway 
in the beneficial action of δ-TT against t-BHP injury, we used 
ML385 a specific Nrf2 inhibitor [40]. As shown in the Fig. 8b, 
we found results similar to those obtained with LY294002 
suggesting the involvement of both cytoprotective pathways 
in δ-TT antioxidant effect. Indeed, when administered together 
LY294002 and ML385, they completely prevented the benefi-
cial effects of δ-TT on cell viability (Fig. 8c).
Effects of δ‑TT on MLO‑Y4 cells viability in basal 
conditions and in the presence of t‑BHP‑induced 
oxidative stress
δ-TT (1.25-20 µg/ml) treatment had no effect on MLO-Y4 
cell viability in basal conditions (Fig. 9a) but was able to 
prevent MLO-Y4 dysfunction induced by t-BHP (125 μM, 
for 3 h). We used t-BHP 125 μM, for 3 h, since MLO-Y4 
cells were more sensitive to damage than MC3T3-E1 cells 
(data not shown). As shown in Fig. 9b, δ-TT exerts differ-
ent effects on cell viability depending on the concentrations 
used. At low concentrations, δ-TT (1.25–5 µg/ml) exerted a 
significant protective effect on MLO-Y4 cell viability and 
apoptosis. However, at the highest concentration (20 µg/ml) 
used, the effects of δ-TT were comparable to those detected 
in t-BHP-treated cells. Treatment with δ-TT (5 µg/ml) sig-
nificantly reduced t-BHP-induced apoptosis (Fig. 10a, b).
Discussion
In the present study, we have shown a stimulatory effect of 
δ-TT on MC3T3-E1 cell viability and provided evidence 
that δ-TT protects both MC3T3-E1 and MLO-Y4 against 
t-BHP-induced oxidative stress.
Fig. 5  Effects of δ-TT on cellular redox imbalance induced by t-BHP 
treatment in MC3T3-E1 cells. Cells were treated with δ-TT (10 µg/
ml) 2 h before being treated with t-BHP (250 µM for 3 h). Intracellu-
lar contents of GSH and GSSG, expressed as nmol/mg protein, were 
measured at 30 (a) and 180 (b) min after t-BHP using the o-phtha-
laldehyde (OPT) fluorimetric assay and the GSH/GSSG ratio was 
determined. Data are the mean ± SEM of six replicates. **p < 0.01, 
***p < 0.001 vs controls; °p < 0.05, °°p < 0.01, °°°p < 0.001 vs t-BHP
Fig. 6  Pre-treatment with BSO (50 µM), an inhibitor of GSH synthe-
sis, reduced the beneficial effects of δ-TT against the excessive gen-
eration of intracellular ROS stimulated by t-BHP in MC3T3-E1 cells. 
The cells were treated with the inhibitor 24 h before receiving δ-TT 
(10  µg/ml) and t-BHP (250  μM) treatments. The intracellular ROS 
levels were measured 30  min after t-BHP using CM-DCFA assay. 
Data are the mean ± SEM of six replicates within a single experiment. 
*p < 0.01, ***p < 0.001 vs controls; °°p < 0.01 vs BSO
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The δ-TT protective effect involves a reduction of intra-
cellular ROS levels and is reflected by the increase of GSH/
GSSG ratio, an indicator of cellular redox state. Finally, 
our data indicate that the interaction between the PI3K/
Akt–Nrf2 pathways is essential in regulating δ-TT beneficial 
effects against oxidative stress in MC3T3-E1 cells.
Our results, showing that purified δ-TT increased cell 
viability in basal conditions, are in line with previous reports 
obtained with long-term incubation of MC3T3-E1 cells with 
annatto-derived TT [41]. Furthermore, annatto TT has been 
shown to enhance the expression of genes involved in bone 
formation and osteoblast activity [42, 43].
We provided the first evidence that δ-TT protects cells 
against t-BHP-induced cell death and apoptosis as evidenced 
Fig. 7  Effects of pre-treatment with a the selective inhibitor of sir-
tuin 1 (EX-527, 25  µM); b farnesylpyrophosphate (FPP, 5  µM) or 
geranylgeranylpyrophosphate (GGPP, 5  µM) on the δ-TT protective 
effect against t-BHP-induced MC3T3-E1 cytotoxicity. The cells were 
treated with each compound 2  h before receiving δ-TT (10  µg/ml) 
and t-BHP (250  μM for 3  h) treatments. Data are the mean ± SEM 
of six replicates within a single experiment. ***p < 0.001 vs controls; 
°°°p < 0.001 vs t-BHP
Fig. 8  Effects of pre-treatment with a a PI3K antagonist (LY294002); 
b an Nrfr2 antagonist (ML385) given alone or in combination c 
on the beneficial action of δ-TT against t-BHP-induced MC3T3-
E1 damage. Cells were treated with LY294002 (10  μM) or ML385 
(7.5 µM) 2 h before δ-TT (10 µg/ml) and t-BHP (250 μM for 3 h). 
MTT assay was performed to analyze cell viability. Data repre-
sented the mean ± SEM of six replicates within a single experiment. 
***p < 0.001 vs controls; °p < 0.05, °°p < 0.01, °°°p < 0.001 vs t-BHP; 
###p < 0.001 vs LY294002 or ML385 + t-BHP
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by MTT assay and Hoechst 33258 staining. The evidence 
that γ-TT is less effective than δ-TT in protecting MC3T3-
E1 cells against oxidative damage indicates that δ-TT might 
be considered the major antioxidant compound in annatto 
seeds.
δ-TT exerts its protective effect against oxidative dam-
age induced by t-BHP by reducing intracellular ROS and 
increasing intracellular antioxidant activity. As an intracel-
lular antioxidant factor potentially involved in the protective 
effects of δ-TT against t-BHP-induced oxidative damage, we 
specifically analyzed GSH. The GSH oxidation to GSSG and 
consequent decrease in the GSH/GSSG ratio are related to 
oxidative stress and are considered a suitable indicator of 
cellular redox state [33, 36].
We found that the decrease in GSH/GSSG ratio detected 
in t-BHP-treated cells was significantly prevented by δ-TT 
pre-treatment since the redox status of GHS was found to 
be similar to that detected in control MC3T3-E1 cells. It is 
possible that the protective effect of δ-TT against ROS levels 
induced by t-BHP could be due to its ability to modulate 
intracellular GSH levels. In fact, GSH depletion by BSO, 
an irreversible inhibitor of the rate-limiting enzyme of GSH 
synthesis, glutamate cysteine ligase (GSL, [34]), signifi-
cantly prevented the positive action of δ-TT on ROS levels.
We then examined the effects of δ-TT against t-BHP-
induced oxidative damage in differentiated MC3T3-E1 cells 
by measuring the expression of several molecules related 
to bone resorption (RANKL and OPG) or bone formation 
(ALP, OC and Col1a). δ-TT did not modify the effects of 
t-BHP on the expression of RANKL, OPG, ALP, OC and 
Col1a (data not shown). The discrepancy between our data 
and previous reports could be due to the different experi-
mental procedure (acute versus long-term treatment with 
δ-TT [42, 43]).
Various cellular signaling pathways participate in the 
maintenance of redox homeostasis. δ-TT treatment was 
found to increase cellular GHS content and attenuate mito-
chondrial ROS levels through activation of Sirtuin-1 which 
is an  NAD+-dependent deacetylase which can modulate a 
variety of histones and non-histone proteins resulting in the 
modification of the expression of several genes involved 
in oxidative stress resistance [44]. However, in our experi-
ments, treatment with the selective inhibitor of sirtuin 1 
(EX-527) failed to prevent the protective action of δ-TT.
Considering that δ-TT was found to down-regulate HMG 
CoA reductase at the transcriptional level [37] and that FPP 
and GGPP, downstream products of mevalonate, negatively 
regulate osteoblast activity [38], we studied whether or not 
the addition of these isoprenoids, by replenishing the meva-
lonate pathway, could prevent the protective action of δ-TT 
against damage induced by t-BHP. At variance with that 
observed for the inhibitory action of annatto TT on bone 
resorption and osteoclast differentiation [17], we observed 
that the mevalonate pathway is not involved in the protective 
action of δ-TT on MC3T3-E1 cells.
To dissect other possible mechanisms which could medi-
ate the δ-TT protection against t-BHP-induced oxidative 
stress, we investigated the PI3K/Akt signaling pathway. This 
pathway plays a key role in the control of osteoblast differ-
entiation and homeostasis [45] as well as in the prevention 
of oxidative stress-induced apoptosis [39].
Pre-treatment with LY294002, a PI3K-specific inhibitor, 
exacerbated the cytotoxic effect of t-BHP on MC3T3-E1 cell 
viability but partially reversed the protective effect of δ-TT.
Another signaling pathway which has emerged as a mas-
ter regulator of intracellular antioxidant response through 
transcriptional activation of antioxidant and detoxifying 
enzymes is the Nrf2 pathway [46, 47]. Interestingly, Nrf2 is 
involved in controlling mitochondrial integrity in response to 
oxidative stress induced by t-BHP [48, 49]. To study the pos-
sible involvement of Nrf2 pathway in the beneficial effects 
of δ-TT against oxidative stress, we pre-treated MC3T3-E1 
cell with ML385, a specific Nrf2 inhibitor able to effec-
tively inhibit Nrf2 nuclear translocation and activation of 
Fig. 9  Effects of δ-TT (1.25–20  µg/ml) on MLO-Y4 cells viability 
measured by MTT assay 2  h after treatment in basal conditions (a) 
and on t-BHP (125 µM for 3 h)-induced cytotoxicity (b). Data are the 
mean ± SEM of six replicates within a single experiment. *p < 0.05, 
***p < 0.001 vs controls; °p < 0.05, °°p < 0.01, °°°p < 0.001 vs t-BHP
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specific target genes [40]. The NRF2 modulates downstream 
genes by binding to their cis-regulatory module antioxidant 
response elements (AREs) NRF2 targets include ARE-
bearing effector genes such ROS scavenging enzymes (e.g., 
superoxide dismutases, SODs), phase-2 defense enzymes 
(e.g., glutathione-S-transferase, GST; HO-1 and NAD(P)H 
quinone oxidoreductase (NQO1), [50]).
In the presence of ML385, we found results similar to 
those obtained with LY294002 suggesting the involvement 
of both cytoprotective pathways in the δ-TT antioxidant 
effect. Indeed, when administered together, LY294002 and 
ML385 completely prevented the beneficial effects of δ-TT 
on cell viability. This is not surprising since cytoprotective 
systems are organized as interactive communication net-
works that are finely turned by regulators and are critical 
features of physiological signaling designed to protect cells 
against endogenous or exogenous stressors. We are aware of 
some limitations of our study since the molecular pathways 
involved in the functional interaction between PI3/Akt and 
Nrf2 pathways in modulating the protective action of δ-TT 
against oxidative stress remain to be clarified. However, con-
sidering the complex interaction between these signaling 
pathways, a clear understanding of the molecular events that 
regulate the cross-talk between PI3/Akt and the antioxidant 
Nrf2 pathway, in the presence of δ-TT, should be the object 
of further studies. It could be interesting to study whether 
the activation of PI3/Akt is a prerequisite for the action of 
δ-TT on Nfr2 activity and the downstream proteins of PI3/
Akt involved in controlling Nfr2. Among protein kinase 
downstream of Akt, GSK-3β was reported to directly phos-
phorylate Nfr2 [51]. Moreover, the activation of Nrf2/ARE 
signaling may also rely on Nrf2 phosphorylation by multiple 
cellular kinases such as protein kinase C and MAP kinase 
[52].
Han et  al. [53] have shown that activation of PI3K/
Akt pathway represents a critical upstream signaling in 
regulating Nrf2 activity. It has been reported the ability of 
LY294002 to reduce Nrf2 translocation into the nucleus 
[53] and the cross-talk between PI3K/Akt and Nrf2 may 
determine the signals to govern the cellular defence sys-
tems against oxidative stress [54] leading to the transcription 
of several cytoprotective genes such as heme oxygenase 1 
(HO-1), and GSL [46, 55]. Our data suggest that δ-TT pro-
tective action against ROS induction by t-BHP involves a 
modulation of intracellular GSH levels by promoting GSH 
synthesis since treatment with BSO, a specific inhibitor of 
GSH synthesis, significantly prevented the protective action 
of δ-TT on ROS levels. The possibility that this protective 
Fig. 10  Effects of δ-TT on apoptosis induced by t-BHP in MLO-
Y4 cells. Cells were treated with δ-TT (5  µg/ml) 2  h before t-BHP 
(125 µM for 3 h). Apoptosis was evaluated by Hoechst 33258 stain-
ing. a Panels show chromatin nuclear condensation typical of apop-
totic cells. Images were taken at × 20 magnification. b Quantification 
of apoptosis. Values are the mean ± SEM of duplicate determinations 
(200 cells each) of four independent experiments. ***p < 0.001 vs 
controls; °°p < 0.01 vs t-BHP
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action of δ-TT could be due to Nrf2 activation is in line 
with previous reports showing that Nrf2 controls both 
basal and inducible expression of genes that encode GLC 
[56] and with preliminary data showing that ML385 pre-
vents the reduction of ROS levels induced by δ-TT after 
30  min of incubation with t-BHP (t-BHP: 347% ± 46; 
δ-TT + t-BHP: 165% ± 22; ML35 + t-BHP: 428% ± 32 
ML35 + δ-TT + t-BHP: 344% ± 35. Data are expressed as 
mean percentage vs control.
Activation of PI3K by δ-TT could not only interact with 
the Nrf2 pathway leading to the induction of various stress 
responsive proteins, but may also promote cell survival by 
enhancing the expression of antiapoptotic proteins such as 
Bcl-2 and inhibiting the activity of pro-apoptotic molecules 
(Bax and caspase-3) in parallel [57].
Accumulating evidence supports a central role for osteo-
cytes in bone remodeling, mineralization and in the repair 
of microdamages and microfractures [58, 59]. Osteocytes, 
which represent 90% of the bone cell population, are derived 
from mature osteoblasts embedded in bone matrix. They are 
mechanosensitive cells and can orchestrate the activity of 
osteoblasts and osteoclasts, thus preventing alterations in 
bone remodeling and bone mass. Osteocyte apoptosis, in 
fact, causes an imbalance in bone remodeling and an impair-
ment of bone to adaptively respond to mechanical loading 
and to repair microdamage due to physiological or patho-
logical events [27, 58, 59].
Excessive oxidative stress induces apoptosis of osteocytes 
[1] and recently it has been reported the ability of increased 
GSH levels to counteract oxidative stress-induced osteocyte 
apoptosis [60]. This study provides the first evidence that 
δ-TT prevents t-BHP-induced apoptosis of the MLO-Y4 
osteocyte-like cell line, which has similar phenotype and 
shares many characteristics of mature osteocytes and repre-
sent a model to study osteocyte viability and apoptosis [61]. 
Further studies will planned to clarify the δ-TT action at the 
molecular level in MLO-Y4 cells and its ability to modify 
the expression of factors such as RANKL, osteoprotegerin, 
Dkk1 and sclerostin, involved in the control of osteoclast 
and osteoblast activity.
One major point to bear in mind to translate in vitro 
results obtained with functional food products into poten-
tial health benefits in living organisms is the pharmacoki-
netic profile of the natural compound used. Alfa-tocopherol 
is the most bioavailable form of vitamin E and is consid-
ered the predominant isoform to be accumulated in tis-
sues when orally administered [22]. Despite the fact that 
TT showed limited absorption and lower bioavailabil-
ity than α-tocopherol, recent evidence indicated that TTs 
have better anti-inflammatory and antioxidant activities 
over α-tocopherol [11] and revealed more efficacy than 
α-tocopherol in protecting animals from platelet aggregation 
[62] and bone loss [12, 13]. Several methods have been used 
to improve the oral availability of lipophilic compounds such 
as TTs. Since emulsions are known to increase absorption of 
fat soluble compounds, self-emulsifying formulations of TTs 
able to induce a threefold increase in TTs plasma concentra-
tion in humans were produced [22, 63]. It is worth noting 
that δ-TT was found to be safe for human consumption [64] 
even at doses as high as 3200 mg/day [65].
In conclusion, the present study provides evidence that 
δ-TT exerts a strong inhibitory action on t-BHP-induced oxi-
dative stress both in MC3T3-E1 osteoblastic and in MLO-Y4 
osteocyte-like cells. The ability of δ-TT to reduce bone loss 
in experimental and clinical conditions of osteoporosis could 
be due to a complex and coordinated action on bone cell 
activities. In particular, δ-TT could have an important role 
in maintaining bone health in condition of excessive ROS 
production such as aging by increasing osteoblast activity 
and by reducing an excessive apoptosis of osteocytes result-
ing in an unbalance of the remodeling process.
δ-TT protective effect in MC3T3-E1 cells is due to a 
reduction of intracellular ROS levels, is reflected by the 
increase of the GSH/GSSG ratio, and involves an interaction 
between the PI3K/Akt–Nrf2 signaling pathways.
Acknowledgements This work was supported by funds from PRO-
GETTO CARIPLO GIOVANI, Fondazione Cariplo (0834-2015) to 
Lavinia Casati. We acknowledge Prof. Giangiacomo Beretta (Dipar-
timento di Scienze e Politiche Ambientali, Università degli Studi 
di Milano), for the kind supply of δ-TT and γ-TT and Dr. Milena 
Romanello (Hospital “Santa Maria della Misericordia”, Udine, Italy) 
for the kind supply of MLO-Y4 cells. The technical support of Dr Mar-
tina Aschedamini was highly appreciated from the authors.
Compliance with ethical standards 
Conflict of interest The authors report that there are no conflicts of 
interest in this paper.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Domazetovic V, Marcucci G, Iantomasi T, Brandi ML, Vincenzini 
MT (2017) Oxidative stress in bone remodeling: role of antioxi-
dants. Clin Cases Miner Bone Metab 14(2):209–216. https ://doi.
org/10.11138 /ccmbm /2017.14.1.209
 2. Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy 
GR (1990) Oxygen-derived free radicals stimulate osteoclastic 
bone resorption in rodent bone in vitro and in vivo. J Clin Investig 
85(3):632–639. https ://doi.org/10.1172/JCI11 4485
 3. Lean JM, Jagger CJ, Kirstein B, Fuller K, Chambers TJ (2005) 
Hydrogen peroxide is essential for estrogen-deficiency bone loss 
European Journal of Nutrition 
1 3
and osteoclast formation. Endocrinology 146(2):728–735. https 
://doi.org/10.1210/en.2004-1021
 4. Bai XC, Lu D, Liu AL, Zhang ZM, Li XM, Zou ZP, Zeng WS, 
Cheng BL, Luo SQ (2005) Reactive oxygen species stimulates 
receptor activator of NF-kappaB ligand expression in osteoblast. 
J Biol Chem 280(17):17497–17506. https ://doi.org/10.1074/jbc.
M4093 32200 
 5. Almeida M, Han L, Martin-Millan M, Plotkin LI, Stewart SA, 
Roberson PK, Kousteni S, O’Brien CA, Bellido T, Parfitt AM, 
Weinstein RS, Jilka RL, Manolagas SC (2007) Skeletal involu-
tion by age-associated oxidative stress and its acceleration by loss 
of sex steroids. J Biol Chem 282(37):27285–27297. https ://doi.
org/10.1074/jbc.M7028 10200 
 6. Casati L, Pagani F, Fibiani M, Lo Scalzo R, Sibilia V (2018) 
Potential of delphinidin-3-rutinoside extracted from Solanum 
melongena L. as promoter of osteoblastic MC3T3-E1 function 
and antagonist of oxidative damage. Eur J Nutr. https ://doi.
org/10.1007/s0039 4-018-1618-0
 7. Banfi G, Iorio EL, Corsi MM (2008) Oxidative stress, free radicals 
and bone remodeling. Clin Chem Lab Med 46(11):1550–1555. 
https ://doi.org/10.1515/CCLM.2008.302
 8. Nojiri H, Saita Y, Morikawa D, Kobayashi K, Tsuda C, Miyazaki 
T, Saito M, Marumo K, Yonezawa I, Kaneko K, Shirasawa T, 
Shimizu T (2011) Cytoplasmic superoxide causes bone fragil-
ity owing to low-turnover osteoporosis and impaired collagen 
cross-linking. J Bone Miner Res 26(11):2682–2694. https ://doi.
org/10.1002/jbmr.489
 9. Prasad G, Dhillon MS, Khullar M, Nagi ON (2003) Evaluation of 
oxidative stress after fractures. A preliminary study. Acta Orthop 
Belg 69(6):546–551
 10. Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, 
Mecocci P, Senin U, Pacifici R, Cherubini A (2003) Marked 
decrease in plasma antioxidants in aged osteoporotic women: 
results of a cross-sectional study. J Clin Endocrinol Metab 
88(4):1523–1527. https ://doi.org/10.1210/jc.2002-02149 6
 11. Aggarwal BB, Sundaram C, Prasad S, Kannappan R (2010) 
Tocotrienols, the vitamin E of the 21st century: its potential 
against cancer and other chronic diseases. Biochem Pharmacol 
80(11):1613–1631. https ://doi.org/10.1016/j.bcp.2010.07.043
 12. Ahmad NS, Khalid BA, Luke DA, Ima Nirwana S (2005) Tocot-
rienol offers better protection than tocopherol from free rad-
ical-induced damage of rat bone. Clin Exp Pharmacol Physiol 
32(9):761–770. https ://doi.org/10.1111/j.1440-1681.2005.04264 
.x
 13. Norazlina M, Hermizi H, Faizah O, Nazrun AS, Norliza M, Ima-
Nirwana S (2010) Vitamin E reversed nicotine-induced toxic 
effects on bone biochemical markers in male rats. Arch Med Sci 
AMS 6(4):505–512. https ://doi.org/10.5114/aoms.2010.14460 
 14. Fujita K, Iwasaki M, Ochi H, Fukuda T, Ma C, Miyamoto T, Taki-
tani K, Negishi-Koga T, Sunamura S, Kodama T, Takayanagi H, 
Tamai H, Kato S, Arai H, Shinomiya K, Itoh H, Okawa A, Takeda 
S (2012) Vitamin E decreases bone mass by stimulating osteoclast 
fusion. Nat Med 18(4):589–594. https ://doi.org/10.1038/nm.2659
 15. Chin KY, Ima-Nirwana S (2014) The effects of alpha-tocopherol 
on bone: a double-edged sword? Nutrients 6(4):1424–1441. https 
://doi.org/10.3390/nu604 1424
 16. Soelaiman IN, Ming W, Abu Bakar R, Hashnan NA, Mohd Ali 
H, Mohamed N, Muhammad N, Shuid AN (2012) Palm tocot-
rienol supplementation enhanced bone formation in oestro-
gen-deficient rats. Int J Endocrinol 2012:532862. https ://doi.
org/10.1155/2012/53286 2
 17. Deng L, Ding Y, Peng Y, Wu Y, Fan J, Li W, Yang R, Yang 
M, Fu Q (2014) Gamma-tocotrienol protects against ovariec-
tomy-induced bone loss via mevalonate pathway as HMG-CoA 
reductase inhibitor. Bone 67:200–207. https ://doi.org/10.1016/j.
bone.2014.07.006
 18. Abdul-Majeed S, Mohamed N, Soelaiman IN (2012) Effects of 
tocotrienol and lovastatin combination on osteoblast and osteo-
clast activity in estrogen-deficient osteoporosis. Evid Based 
Complement Altern Med eCAM 2012:960742. https ://doi.
org/10.1155/2012/96074 2
 19. Chin KY, Ima-Nirwana S (2014) Effects of annatto-derived 
tocotrienol supplementation on osteoporosis induced by tes-
tosterone deficiency in rats. Clin Interv Aging 9:1247–1259. 
https ://doi.org/10.2147/CIA.S6701 6
 20. Mohamad NV, Ima-Nirwana S, Chin KY (2018) Effect of tocot-
rienol from Bixa orellana (annatto) on bone microstructure, 
calcium content, and biomechanical strength in a model of 
male osteoporosis induced by buserelin. Drug Des Dev Ther 
12:555–564. https ://doi.org/10.2147/DDDT.S1584 10
 21. Rondanelli M, Faliva MA, Peroni G, Moncaglieri F, Infantino 
V, Naso M, Perna S (2015) Focus on pivotal role of dietary 
intake (diet and supplement) and blood levels of tocopherols 
and tocotrienols in obtaining successful aging. Int J Mol Sci 
16(10):23227–23249. https ://doi.org/10.3390/ijms1 61023 227
 22. Peh HY, Tan WS, Liao W, Wong WS (2016) Vitamin E therapy 
beyond cancer: tocopherol versus tocotrienol. Pharmacol Ther 
162:152–169. https ://doi.org/10.1016/j.pharm thera .2015.12.003
 23. Shen CL, Klein A, Chin KY, Mo H, Tsai P, Yang RS, Chyu MC, 
Ima-Nirwana S (2017) Tocotrienols for bone health: a transla-
tional approach. Ann N Y Acad Sci 1401(1):150–165. https ://
doi.org/10.1111/nyas.13449 
 24. Shen CL, Yang S, Tomison MD, Romero AW, Felton CK, Mo H 
(2018) Tocotrienol supplementation suppressed bone resorption 
and oxidative stress in postmenopausal osteopenic women: a 
12-week randomized double-blinded placebo-controlled trial. 
Osteoporos Int 29(4):881–891. https ://doi.org/10.1007/s0019 
8-017-4356-x
 25. Altman SA, Zastawny TH, Randers L, Lin ZL, Lumpkin JA, 
Remacle J, Dizdaroglu M, Rao G (1994) Tert-butyl hydrop-
eroxide-mediated DNA-base damage in cultured-mammalian-
cells. Mutat Res 306(1):35–44. https ://doi.org/10.1016/0027-
5107(94)90165 -1
 26. Dieci E, Casati L, Pagani F, Celotti F, Sibilia V (2014) Acylated 
and unacylated ghrelin protect MC3T3-E1 cells against tert-
butyl hydroperoxide-induced oxidative injury: pharmacologi-
cal characterization of ghrelin receptor and possible epige-
netic involvement. Amino Acids 46(7):1715–1725. https ://doi.
org/10.1007/s0072 6-014-1734-y
 27. Bonewald LF (2011) The amazing osteocyte. J Bone Miner Res 
26(2):229–238. https ://doi.org/10.1002/jbmr.320
 28. Montagnani Marelli M, Marzagalli M, Moretti RM, Beretta G, 
Casati L, Comitato R, Gravina GL, Festuccia C, Limonta P 
(2016) Vitamin E delta-tocotrienol triggers endoplasmic reticu-
lum stress-mediated apoptosis in human melanoma cells. Sci 
Rep 6:30502. https ://doi.org/10.1038/srep3 0502
 29. Casati L, Pagani F, Braga PC, Lo Scalzo R, Sibilia V (2016) 
Nasunin, a new player in the field of osteoblast protection 
against oxidative stress. J Funct Foods 23:474–484. https ://doi.
org/10.1016/j.jff.2016.03.007
 30. Hissin PJ, Hilf R (1976) A fluorometric method for determina-
tion of oxidized and reduced glutathione in tissues. Anal Bio-
chem 74(1):214–226
 31. Shen J, Yang T, Xu Y, Luo Y, Zhong X, Shi L, Hu T, Guo T, 
Nie Y, Luo F, Lin Q (2018) delta-Tocotrienol, isolated from 
rice bran, exerts an anti-inflammatory effect via MAPKs and 
PPARs signaling pathways in lipopolysaccharide-stimulated 
macrophages. Int J Mol Sci. https ://doi.org/10.3390/ijms1 91030 
22
 32. Wang C, Husain K, Zhang A, Centeno BA, Chen DT, Tong Z, 
Sebti SM, Malafa MP (2015) EGR-1/Bax pathway plays a role in 
vitamin E delta-tocotrienol-induced apoptosis in pancreatic cancer 
 European Journal of Nutrition
1 3
cells. J Nutr Biochem 26(8):797–807. https ://doi.org/10.1016/j.
jnutb io.2015.02.008
 33. Jones DP (2002) Redox potential of GSH/GSSG couple: assay and 
biological significance. Methods Enzymol 348:93–112
 34. Griffith OW, Meister A (1979) Potent and specific inhibition of 
glutathione synthesis by buthionine sulfoximine (S-n-butyl homo-
cysteine sulfoximine). J Biol Chem 254(16):7558–7560
 35. Li Q, Yin X, Wang W, Zhan M, Zhao B, Hou Z, Wang J (2016) 
The effects of buthionine sulfoximine on the proliferation and 
apoptosis of biliary tract cancer cells induced by cisplatin and 
gemcitabine. Oncol Lett 11(1):474–480. https ://doi.org/10.3892/
ol.2015.3879
 36. Romagnoli C, Marcucci G, Favilli F, Zonefrati R, Mavilia C, Galli 
G, Tanini A, Iantomasi T, Brandi ML, Vincenzini MT (2013) Role 
of GSH/GSSG redox couple in osteogenic activity and osteoclas-
togenic markers of human osteoblast-like SaOS-2 cells. FEBS J 
280(3):867–879. https ://doi.org/10.1111/febs.12075 
 37. Song BL, DeBose-Boyd RA (2006) Insig-dependent ubiquitina-
tion and degradation of 3-hydroxy-3-methylglutaryl coenzyme a 
reductase stimulated by delta- and gamma-tocotrienols. J Biol 
Chem 281(35):25054–25061. https ://doi.org/10.1074/jbc.M6055 
75200 
 38. Ruan F, Zheng Q, Wang J (2012) Mechanisms of bone anabo-
lism regulated by statins. Biosci Rep 32(6):511–519. https ://doi.
org/10.1042/BSR20 11011 8
 39. Wang B, Shravah J, Luo H, Raedschelders K, Chen DD, Ansley 
DM (2009) Propofol protects against hydrogen peroxide-induced 
injury in cardiac H9c2 cells via Akt activation and Bcl-2 up-reg-
ulation. Biochem Biophys Res Commun 389(1):105–111. https ://
doi.org/10.1016/j.bbrc.2009.08.097
 40. Singh A, Venkannagari S, Oh KH, Zhang YQ, Rohde JM, Liu 
L, Nimmagadda S, Sudini K, Brimacombe KR, Gajghate S, 
Ma J, Wang A, Xu X, Shahane SA, Xia M, Woo J, Mensah GA, 
Wang Z, Ferrer M, Gabrielson E, Li Z, Rastinejad F, Shen M, 
Boxer MB, Biswal S (2016) Small molecule inhibitor of NRF2 
selectively intervenes therapeutic resistance in KEAP1-deficient 
NSCLC tumors. ACS Chem Biol 11(11):3214–3225. https ://doi.
org/10.1021/acsch embio .6b006 51
 41. Wan Hasan WN, Abd Ghafar N, Chin KY, Ima-Nirwana S (2018) 
Annatto-derived tocotrienol stimulates osteogenic activity in pre-
osteoblastic MC3T3-E1 cells: a temporal sequential study. Drug 
Des Dev Ther 12:1715–1726. https ://doi.org/10.2147/DDDT.
S1689 35
 42. Abukhadir SS, Mohamed N, Makpol S, Muhammad N (2012) 
Effects of palm vitamin E on bone-formation-related gene expres-
sion in nicotine-treated rats. Evid Based Complement Altern Med 
eCAM 2012:656025. https ://doi.org/10.1155/2012/65602 5
 43. Chin KY, Ima-Nirwana S (2015) The biological effects of tocot-
rienol on bone: a review on evidence from rodent models. Drug 
Des Dev Ther 9:2049–2060. https ://doi.org/10.2147/Dddt.S7966 
0
 44. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R (2012) 
Are sirtuins viable targets for improving healthspan and lifespan? 
Nat Rev Drug Discov 11(6):443–461. https ://doi.org/10.1038/
nrd37 38
 45. McGonnell IM, Grigoriadis AE, Lam EW, Price JS, Sunters A 
(2012) A specific role for phosphoinositide 3-kinase and AKT in 
osteoblasts? Front Endocrinol 3:88. https ://doi.org/10.3389/fendo 
.2012.00088 
 46. Loboda A, Damulewicz M, Pyza E, Jozkowicz A, Dulak J 
(2016) Role of Nrf2/HO-1 system in development, oxidative 
stress response and diseases: an evolutionarily conserved mecha-
nism. Cell Mol Life Sci CMLS 73(17):3221–3247. https ://doi.
org/10.1007/s0001 8-016-2223-0
 47. Min KJ, Lee JT, Joe EH, Kwon TK (2011) An IkappaBalpha 
phosphorylation inhibitor induces heme oxygenase-1(HO-1) 
expression through the activation of reactive oxygen species 
(ROS)-Nrf2–ARE signaling and ROS-PI3K/Akt signaling in an 
NF-kappaB-independent mechanism. Cell Signal 23(9):1505–
1513. https ://doi.org/10.1016/j.cells ig.2011.05.013
 48. Greco T, Fiskum G (2010) Brain mitochondria from rats treated 
with sulforaphane are resistant to redox-regulated permeability 
transition. J Bioenerg Biomembr 42(6):491–497. https ://doi.
org/10.1007/s1086 3-010-9312-9
 49. Greco T, Shafer J, Fiskum G (2011) Sulforaphane inhibits mito-
chondrial permeability transition and oxidative stress. Free Radic 
Biol Med 51(12):2164–2171. https ://doi.org/10.1016/j.freer adbio 
med.2011.09.017
 50. Kobayashi M, Yamamoto M (2005) Molecular mechanisms acti-
vating the Nrf2–Keap1 pathway of antioxidant gene regulation. 
Antioxid Redox Signal 7(3–4):385–394. https ://doi.org/10.1089/
ars.2005.7.385
 51. Salazar M, Rojo AI, Velasco D, de Sagarra RM, Cuadrado A 
(2006) Glycogen synthase kinase-3beta inhibits the xenobiotic 
and antioxidant cell response by direct phosphorylation and 
nuclear exclusion of the transcription factor Nrf2. J Biol Chem 
281(21):14841–14851. https ://doi.org/10.1074/jbc.M5137 37200 
 52. Kwak MK, Kensler TW (2010) Targeting NRF2 signaling for 
cancer chemoprevention. Toxicol Appl Pharmacol 244(1):66–76. 
https ://doi.org/10.1016/j.taap.2009.08.028
 53. Han D, Chen W, Gu X, Shan R, Zou J, Liu G, Shahid M, Gao J, 
Han B (2017) Cytoprotective effect of chlorogenic acid against 
hydrogen peroxide-induced oxidative stress in MC3T3-E1 cells 
through PI3K/Akt-mediated Nrf2/HO-1 signaling pathway. Onco-
target 8(9):14680–14692. https ://doi.org/10.18632 /oncot arget 
.14747 
 54. Nakaso K, Yano H, Fukuhara Y, Takeshima T, Wada-Isoe K, 
Nakashima K (2003) PI3K is a key molecule in the Nrf2-mediated 
regulation of antioxidative proteins by hemin in human neuroblas-
toma cells. FEBS Lett 546(2–3):181–184
 55. Copple IM, Goldring CE, Kitteringham NR, Park BK (2008) 
The Nrf2–Keap1 defence pathway: role in protection against 
drug-induced toxicity. Toxicology 246(1):24–33. https ://doi.
org/10.1016/j.tox.2007.10.029
 56. Lee HR, Cho JM, Shin DH, Yong CS, Choi HG, Wakabayashi 
N, Kwak MK (2008) Adaptive response to GSH depletion and 
resistance to l-buthionine-(S,R)-sulfoximine: involvement of 
Nrf2 activation. Mol Cell Biochem 318(1–2):23–31. https ://doi.
org/10.1007/s1101 0-008-9853-y
 57. Downward J (2004) PI 3-kinase, Akt and cell survival. Semin Cell 
Dev Biol 15(2):177–182
 58. Henriksen K, Neutzsky-Wulff AV, Bonewald LF, Karsdal MA 
(2009) Local communication on and within bone controls bone 
remodeling. Bone 44(6):1026–1033. https ://doi.org/10.1016/j.
bone.2009.03.671
 59. Verborgt O, Gibson GJ, Schaffler MB (2000) Loss of osteocyte 
integrity in association with microdamage and bone remodeling 
after fatigue in vivo. J Bone Miner Res 15(1):60–67. https ://doi.
org/10.1359/jbmr.2000.15.1.60
 60. Fontani F, Marcucci G, Iantomasi T, Brandi ML, Vincenzini MT 
(2015) Glutathione, N-acetylcysteine and lipoic acid down-reg-
ulate starvation-induced apoptosis, RANKL/OPG ratio and scle-
rostin in osteocytes: involvement of JNK and ERK1/2 signalling. 
Calcif Tissue Int 96(4):335–346. https ://doi.org/10.1007/s0022 
3-015-9961-0
 61. Bonewald LF, Johnson ML (2008) Osteocytes, mechanosensing 
and Wnt signaling. Bone 42(4):606–615. https ://doi.org/10.1016/j.
bone.2007.12.224
European Journal of Nutrition 
1 3
 62. Qureshi AA, Karpen CW, Qureshi N, Papasian CJ, Morrison 
DC, Folts JD (2011) Tocotrienols-induced inhibition of plate-
let thrombus formation and platelet aggregation in stenosed 
canine coronary arteries. Lipids Health Dis 10:58. https ://doi.
org/10.1186/1476-511X-10-58
 63. Gao P, Morozowich W (2006) Development of supersaturatable 
self-emulsifying drug delivery system formulations for improving 
the oral absorption of poorly soluble drugs. Expert Opin Drug 
Deliv 3(1):97–110. https ://doi.org/10.1517/17425 247.3.1.97
 64. Mahipal A, Klapman J, Vignesh S, Yang CS, Neuger A, Chen 
DT, Malafa MP (2016) Pharmacokinetics and safety of vitamin E 
delta-tocotrienol after single and multiple doses in healthy sub-
jects with measurement of vitamin E metabolites. Cancer Chem-
other Pharmacol 78(1):157–165. https ://doi.org/10.1007/s0028 
0-016-3048-0
 65. Springett GM, Husain K, Neuger A, Centeno B, Chen DT, Hutch-
inson TZ, Lush RM, Sebti S, Malafa MP (2015) A phase I safety, 
pharmacokinetic, and pharmacodynamic presurgical trial of vita-
min E delta-tocotrienol in patients with pancreatic ductal neopla-
sia. EBioMedicine 2(12):1987–1995. https ://doi.org/10.1016/j.
ebiom .2015.11.025
